Summary
Sodium Chloride has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in NAFLD / MASH (Metabolic-Associated Steatohepatitis) would be drug repurposing rather than first-in-human development. This does not mean it is approved for NAFLD / MASH (Metabolic-Associated Steatohepatitis). ClinicalTrials.gov lists 1 registered trial linking Sodium Chloride to NAFLD / MASH (Metabolic-Associated Steatohepatitis): 1 is active or not yet recruiting. None of the registered studies carries a drug-development phase label, which is typical for behavioural, device and supplement protocols. It plans or enrolled 90 participants. Registered activity dates to 2026. The literature layer holds 1 publication for this pair: 1 clinical trial publication. The dated items are from 2013. These are primary trial reports rather than syntheses, so results have not yet been pooled or graded independently.
The RepurpOS disease-intelligence file for Metabolic Dysfunction-Associated Steatohepatitis ranks 292 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: MASH (formerly NASH) with fibrosis progresses to cirrhosis in ~20% over 10 years on standard care (which until 2024 was lifestyle modification only); fibrosis regression occurs spontaneously in ~25% over 5 years with sustained weight loss.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 24.0 (trials 2.0, literature 2.0, tier 15, approved bonus 5.0) |
| Registered trials | 1 total: 0 recruiting, 1 active / not yet recruiting, 0 completed, 0 other |
| Linked publications | 1 (1 clinical trial publication) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | DGIdb |
| Linked via biomarker / target | AGTR1 |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT07391267 | Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide. 2026 | not yet recruiting | Not applicable | 90 |
Published literature
- Clinical trial publication [Metabolic correction of dyslipidemia in patients with nonalcoholic fatty liver disease as a new therapy policy]Stel'makh VV, Kozlov VK · Terapevticheskii arkhiv · 2013 · PMID 23808297
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target AGTR1. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Sodium Chloride approved for NAFLD / MASH (Metabolic-Associated Steatohepatitis)?
Sodium Chloride has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in NAFLD / MASH (Metabolic-Associated Steatohepatitis) would be drug repurposing rather than first-in-human development. This does not mean it is approved for NAFLD / MASH (Metabolic-Associated Steatohepatitis). Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Sodium Chloride in clinical trials for NAFLD / MASH (Metabolic-Associated Steatohepatitis)?
ClinicalTrials.gov lists 1 registered trial linking Sodium Chloride to NAFLD / MASH (Metabolic-Associated Steatohepatitis): 1 is active or not yet recruiting. None of the registered studies carries a drug-development phase label, which is typical for behavioural, device and supplement protocols. It plans or enrolled 90 participants. Registered activity dates to 2026.
What does the evidence show for Sodium Chloride in NAFLD / MASH (Metabolic-Associated Steatohepatitis)?
Trials of Sodium Chloride in NAFLD / MASH (Metabolic-Associated Steatohepatitis) are registered but none has completed, so there is no outcome evidence from those studies yet; the record is a signal of research interest. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target AGTR1. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.